A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation

Merck Sharp and Dohme0 个研究点目标入组 615 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•- Patient is pregnant, breast-feeding, or expecting to become pregnant during the study
•- Patient routinely consumes more than 2 alcoholic drinks per day
•- Patient has known or suspected prolonged QT, familial long QT syndrome, previous Torsades de Pointes, Brugada syndrome
•- Patient has known bradycardia, advanced AV block, or sick-sinus syndrome, unless controlled by a pacemaker
•- Patient has severe aortic stenosis
•- Patient has atrial flutter
•- Patient has Class IV congestive heart failure (CHF)
•- Patient has had a myocardial infarction (MI) or acute coronary syndrome (ACS)
•- Patient has had cardiac surgery within 30 days
•- Patient has known atrial thrombus
•- Patient has reversible causes of Atrial Fibrillation
•- Patient has failed electrical cardioversion during current episode of Atrial Fibrillation
•- Patient has uncorrected electrolyte imbalance
•- Patient has clinical evidence of digoxin toxicity
•- Patient has received certain antiarrhythmic drugs or intravenous amiodarone within 7 days
•- Patient is known to be HIV positive
•- Patient has a history of cancer within the past 5 years, except for certain skin or cervical cancers
•-Ejection Fraction 35%.

发起方

Merck Sharp and Dohme